Occurrence and risk factors for benign epithelial gastric polyps in atrophic body gastritis on diagnosis and follow-up.

Abstract:

BACKGROUND:Benign epithelial gastric polyps have been reported to be more common in atrophic body gastritis. The role of Helicobacter pylori infection in the induction of gastric atrophy is well-known. The development of hyperplastic polyps may be in relation to H. pylori infection. AIM:To investigate occurrence of benign epithelial gastric polyps in atrophic body gastritis patients at diagnosis and follow-up, and the role of H. pylori and other risk factors for the development of benign epithelial gastric polyps. METHODS:A total of 259 consecutive atrophic body gastritis patients included in a follow-up programme, of whom 202 were followed up for median period of 4 years (range: 2-11). At baseline and follow-up gastroscopies, the presence of benign epithelial gastric polyps was evaluated. Biopsies for histology were obtained from all detected benign epithelial gastric polyps. RESULTS:Frequency of benign epithelial gastric polyps in atrophic body gastritis patients were 4.6% at baseline and 5.9% at follow-up. About 91.7% were hyperplastic polyps. H. pylori infection was detected in 79.2% atrophic body gastritis patients with benign epithelial gastric polyps, and in 70.8% without benign epithelial gastric polyps. Smoking was more frequent among patients with benign epithelial gastric polyps [42% vs. 20%, OR 2.8 (95% CI: 1.2-6.9)]. CONCLUSIONS:Benign epithelial gastric polyps occur in about 5% of atrophic body gastritis patients, and the vast majority are hyperplastic polyps. Smoking habit, but not H. pylori infection, increases the risk for benign epithelial gastric polyps in atrophic body gastritis patients.

journal_name

Aliment Pharmacol Ther

authors

Di Giulio E,Lahner E,Micheletti A,Milione M,D'Ambra G,Bordi C,Delle Fave G,Annibale B

doi

10.1111/j.1365-2036.2005.02399.x

subject

Has Abstract

pub_date

2005-03-01 00:00:00

pages

567-74

issue

5

eissn

0269-2813

issn

1365-2036

pii

APT2399

journal_volume

21

pub_type

杂志文章
  • The efficacy and safety of direct acting antiviral treatment and clinical significance of drug-drug interactions in elderly patients with chronic hepatitis C virus infection.

    abstract:BACKGROUND:Direct antiviral therapies for chronic hepatitis C virus (HCV) infection have expanded treatment options for neglected patient populations, including elderly patients who are ineligible/intolerant to receive interferon (IFN)-based therapy. AIM:To investigate the efficacy, tolerability and potential for drug...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.13769

    authors: Vermehren J,Peiffer KH,Welsch C,Grammatikos G,Welker MW,Weiler N,Zeuzem S,Welzel TM,Sarrazin C

    更新日期:2016-10-01 00:00:00

  • Noncoeliac enteropathy: the differential diagnosis of villous atrophy in contemporary clinical practice.

    abstract:BACKGROUND:Duodenal villous atrophy (DVA) is a key diagnostic finding in coeliac disease (CD). However, the differential diagnosis for this finding is broad. AIM:To identify conditions causing noncoeliac enteropathy (NCE) with villous atrophy and methods to differentiate between CD and NCE in clinical practice. METHO...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2011.04938.x

    authors: Pallav K,Leffler DA,Tariq S,Kabbani T,Hansen J,Peer A,Bhansali A,Najarian R,Kelly CP

    更新日期:2012-02-01 00:00:00

  • Ascitic cholesterol is superior to serum-ascites albumin gradient in the detection of non-portal hypertensive ascites and the diagnosis of mixed ascites.

    abstract:BACKGROUND:The diagnostic value of ascitic cholesterol in the differential diagnosis of ascites is controversial. AIM:To investigate the diagnostic performance of ascitic cholesterol in the differential diagnosis of ascites. METHODS:Consecutive patients with new-onset ascites were enrolled prospectively. The pertinen...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.15042

    authors: Du L,Zhu S,Lu Z,Xu T,Bai T,Xu D,Wei X,Li J,Xu K,Ye J,Hou X,Song Y

    更新日期:2019-01-01 00:00:00

  • Helicobacter DNA in bile: correlation with hepato-biliary diseases.

    abstract:BACKGROUND:Helicobacter has been identified in isolated cases of hepato-biliary diseases, but its role in the pathogenesis of these conditions remains unclear. AIM:To determine whether Helicobacter could be detected in bile obtained at endoscopic retrograde cholangiopancreatography, and to evaluate the prevalence of t...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1046/j.1365-2036.2003.01424.x

    authors: Fallone CA,Tran S,Semret M,Discepola F,Behr M,Barkun AN

    更新日期:2003-02-01 00:00:00

  • Clinical features, biochemical parameters, and virological profiles of patients with hepatocellular carcinoma in Hong Kong.

    abstract:BACKGROUND:Clinical features of hepatocellular carcinoma patients are changing because of screening. AIM:To examine the clinical features of hepatocellular carcinoma patients in Hong Kong and validity of different staging systems. METHODS:A total of 223 Chinese patients with hepatocellular carcinoma were studied. RE...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2006.03029.x

    authors: Cheung TK,Lai CL,Wong BC,Fung J,Yuen MF

    更新日期:2006-08-15 00:00:00

  • Effect of mefenamic acid on bowel transit time in healthy adult volunteers.

    abstract::The effect of mefenamic acid on bowel transit time was investigated. Seven healthy adult male subjects of age 39 +/- 2.4 years (mean +/- S.E.M.) received placebo or mefenamic acid (500 mg t.d.s) orally in randomized order for five days, with a 7-day washout between studies. On the third morning after starting the drug...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.1990.tb00488.x

    authors: Rashid MU,Bateman DN

    更新日期:1990-08-01 00:00:00

  • Azathioprine and mercaptopurine in the management of patients with chronic, active microscopic colitis.

    abstract:BACKGROUND:Microscopic colitis (MC) is a common chronic diarrhoeal disease, and remission can be induced with budesonide. However, diarrhoea relapses frequently when budesonide is tapered and a few patients become budesonide intolerant. AIM:To examine retrospectively the effect of azathioprine (AZA) and mercaptopurine...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1111/apt.12261

    authors: Münch A,Fernandez-Banares F,Munck LK

    更新日期:2013-04-01 00:00:00

  • A distinct subset of chemokines dominates the mucosal chemokine response in inflammatory bowel disease.

    abstract:BACKGROUND:Inflammatory bowel disease (IBD) is characterised by intense mucosal recruitment of activated leukocytes. Chemokines determine inflammatory leukocyte recruitment and retention. AIM:To compare expression of the entire chemokine family within colonic mucosa from IBD patients and uninflamed controls. METHODS:...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2004.02262.x

    authors: Puleston J,Cooper M,Murch S,Bid K,Makh S,Ashwood P,Bingham AH,Green H,Moss P,Dhillon A,Morris R,Strobel S,Gelinas R,Pounder RE,Platt A

    更新日期:2005-01-15 00:00:00

  • The 12-month safety profile of dexlansoprazole, a proton pump inhibitor with a dual delayed release formulation, in patients with gastro-oesophageal reflux disease.

    abstract:BACKGROUND:Dexlansoprazole MR is a Dual Delayed Release formulation of dexlansoprazole, an enantiomer of lansoprazole, designed to extend the duration of acid suppression. AIM:To assess the 12-month safety of dexlansoprazole MR in patients with symptomatic gastro-oesophageal reflux disease (GERD). METHODS:In this ran...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1111/j.1365-2036.2010.04519.x

    authors: Dabholkar AH,Han C,Paris MM,Perez MC,Atkinson SN,Peura DA

    更新日期:2011-02-01 00:00:00

  • Comparison of two low-dose one-week triple therapy regimens with and without metronidazole for cure of H. pylori infection.

    abstract:BACKGROUND:One-week triple therapy consisting of omeprazole 20 mg b.d., clarithromycin 250 mg b.d. and tinidazole 500 mg b.d. is an effective therapy for H. pylori infection with a cure rate of 93%. We therefore compared two similar 1-week regimens consisting of a lansoprazole, clarithromycin and either metronidazole o...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1111/j.0953-0673.1996.00275.x

    authors: Jaup BH,Norrby A

    更新日期:1996-06-01 00:00:00

  • Development and validation of the chronic hepatitis C virus treatment satisfaction (HCVTSat) instrument.

    abstract:BACKGROUND:While current medications used to treat patients with chronic hepatitis C virus (HCV) effectively produce sustained viral response (SVR), postponement of therapy is often times attributed to patient perceptions of unfavourable outcomes. However, an instrument to assess patient perceptions of therapy (i.e. tr...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.12202

    authors: Szeinbach SL,Baran RW,Dietz B,Gazzouola Rocca L,Littlefield D,Yawn BP

    更新日期:2013-03-01 00:00:00

  • Meta-analysis: colonoscopic post-polypectomy bleeding in patients on continued clopidogrel therapy.

    abstract:BACKGROUND:Current guidelines recommend the cessation of clopidogrel therapy 5 days and 7-10 days prior to colonoscopic polypectomy. Recent studies have advocated for continued clopidogrel as post-polypectomy bleeding (PPB) rates have been similar to those in the general population not on antithrombotic therapy. AIM:T...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,meta分析

    doi:10.1111/apt.12292

    authors: Gandhi S,Narula N,Mosleh W,Marshall JK,Farkouh M

    更新日期:2013-05-01 00:00:00

  • Microbiome changes associated with sustained eradication of Clostridium difficile after single faecal microbiota transplantation in children with and without inflammatory bowel disease.

    abstract:BACKGROUND:Little data are available regarding the effectiveness and associated microbiome changes of faecal microbiota transplantation (FMT) for Clostridium difficile infection (CDI) in children, especially in those with inflammatory bowel disease (IBD) with presumed underlying dysbiosis. AIM:To investigate C. diffic...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.13326

    authors: Hourigan SK,Chen LA,Grigoryan Z,Laroche G,Weidner M,Sears CL,Oliva-Hemker M

    更新日期:2015-09-01 00:00:00

  • Double-blind placebo-controlled multicentre studies of rebamipide, a gastroprotective drug, in the treatment of functional dyspepsia with or without Helicobacter pylori infection.

    abstract:BACKGROUND:Functional dyspepsia is a problem that is difficult to treat in clinical practice. AIM:To evaluate the efficacy and safety of rebamipide (a cytoprotective drug) in functional dyspepsia. METHODS:Patients with functional dyspepsia (n=557) were divided a priori into two studies by Helicobacter pylori status, ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,多中心研究,随机对照试验

    doi:10.1046/j.1365-2036.2001.01074.x

    authors: Talley NJ,Riff DS,Schwartz H,Marcuard SP

    更新日期:2001-10-01 00:00:00

  • Night-time intra-oesophageal bile and acid: a comparison between gastro-oesophageal reflux disease patients who failed and those who were treated successfully with a proton pump inhibitor.

    abstract:BACKGROUND:Little is known about the contribution of bile and acid reflux to night-time symptoms generation in patients who failed PPI treatment. AIM:To compare the degree of night-time oesophageal acid and bile [by the surrogate duodenogastroesophageal reflux (DGER)] exposure between gastro-oesophageal reflux disease...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.2011.04583.x

    authors: Hershcovici T,Jha LK,Cui H,Powers J,Fass R

    更新日期:2011-04-01 00:00:00

  • Effect of Helicobacter pylori eradication on duodenal ulcer scar in patients with no clinical history of duodenal ulcer.

    abstract:BACKGROUND:Helicobacter pylori eradication has become the standard treatment for duodenal ulcer. However, there is no relevant evidence for antibacterial treatment of the white scar stage of duodenal ulcer (duodenal ulcer scar) in patients with no past history of duodenal ulcer. AIM:To investigate whether H. pylori er...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.1046/j.1365-2036.2002.01174.x

    authors: Kim JS,Kim SG,Choi IJ,Park MJ,Kim BG,Jung HC,Song IS

    更新日期:2002-02-01 00:00:00

  • Drug interactions with antisecretory agents.

    abstract::Antisecretory agents may affect the absorption, metabolism, and renal excretion of other drugs. Inhibition of gastric acid secretion may decrease the gastrointestinal absorption of drugs such as ketoconazole that dissolve poorly in the absence of adequate acid. With anti-secretory agents, the drug interaction mechanis...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.1991.tb00755.x

    authors: Hansten PD

    更新日期:1991-01-01 00:00:00

  • Prospective evaluation of ranitidine bismuth citrate-based triple therapy for the treatment of Helicobacter pylori infection.

    abstract:BACKGROUND:There is a need for effective and inexpensive therapy for Helicobacter pylori with good patient compliance. AIM:To evaluate a simplified twice daily schedule for treating H. pylori. METHODS:Patients infected with H. pylori (positive by CLO- and 13C-urea breath tests [UBT]) and not previously treated with a...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1046/j.1365-2036.1999.00509.x

    authors: Mönkemüller KE,Hirschowitz BI

    更新日期:1999-05-01 00:00:00

  • Review article: malnutrition/sarcopenia and frailty in patients with cirrhosis.

    abstract:BACKGROUND:Malnutrition/sarcopenia and frailty are common in patients with cirrhosis and are associated with poor outcomes. AIM:To provide an overview of data on the importance, assessment and management of malnutrition/sarcopenia and frailty in cirrhosis. METHODS:A literature search was conducted in PubMed and other...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/apt.15571

    authors: Bunchorntavakul C,Reddy KR

    更新日期:2020-01-01 00:00:00

  • Review article: clinical evidence to support current therapies of irritable bowel syndrome.

    abstract::This review summarizes the clinical evidence to support current therapies in irritable bowel syndrome (IBS). Fibre is indicated at a dose of at least 12 g per day in patients with constipation-predominant IBS. Loperamide (and probably other opioid agonists) are of proven benefit in diarrhoea-predominant IBS; loperamid...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:

    authors: Camilleri M

    更新日期:1999-05-01 00:00:00

  • Review article: endoscopy-related infections.

    abstract::Endoscopic procedures generate bacteraemia to different degrees. Under certain conditions, most notably valvular heart disease, clinically significant infections may occur. A large body of literature has grown around recommendations for antibiotic prophylaxis to prevent procedure-related infections. Most of this liter...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:

    authors: Schembre D,Bjorkman DJ

    更新日期:1993-08-01 00:00:00

  • Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort.

    abstract:BACKGROUND:Programmed cell death protein-1-targeted immunotherapy has shown promising results in phase II studies of hepatocellular carcinoma. AIM:To evaluate safety and efficacy of nivolumab and pembrolizumab in an international, multicentre, real-world cohort of patients with advanced hepatocellular carcinoma. METH...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1111/apt.15245

    authors: Scheiner B,Kirstein MM,Hucke F,Finkelmeier F,Schulze K,von Felden J,Koch S,Schwabl P,Hinrichs JB,Waneck F,Waidmann O,Reiberger T,Müller C,Sieghart W,Trauner M,Weinmann A,Wege H,Trojan J,Peck-Radosavljevic M,Vogel A

    更新日期:2019-05-01 00:00:00

  • Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man.

    abstract::The bioavailability of three pure 5-aminosalicylic (5-ASA) preparations (Asacol, Claversal, and Pentasa) was studied in 8 ileostomy patients and 12 normal subjects after 6 days of treatment with 2000 mg 5-ASA. The local bioavailability, reflected by the 5-ASA concentration was thereby measured at two clinically releva...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/j.1365-2036.1990.tb00499.x

    authors: Christensen LA,Fallingborg J,Abildgaard K,Jacobsen BA,Sanchez G,Hansen SH,Bondesen S,Hvidberg EF,Rasmussen SN

    更新日期:1990-10-01 00:00:00

  • Neurokinin-1 receptor antagonism in a human model of visceral hypersensitivity.

    abstract:BACKGROUND:Substance P acting via the neurokinin-1 receptor is involved in the development of hyperalgesia, although studies using neurokinin-1 receptor antagonists (NK-1RA) in human somatic pain have been disappointing. AIM:To evaluate whether Substance P is involved in the development of human visceral pain/hyperalg...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1111/j.1365-2036.2006.03190.x

    authors: Willert RP,Hobson AR,Delaney C,Hicks KJ,Dewit OE,Aziz Q

    更新日期:2007-02-01 00:00:00

  • Vedolizumab in the treatment of chronic, antibiotic-dependent or refractory pouchitis.

    abstract:BACKGROUND:The most common complication after ileal pouch anal anastomosis in up to 50% of patients is an acute pouchitis. The majority of patients respond to antibiotic treatment. However, 10%-15% develops chronic antibiotic-dependent or refractory pouchitis which is usually hard to treat. AIM:To evaluate the effecti...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1111/apt.14479

    authors: Bär F,Kühbacher T,Dietrich NA,Krause T,Stallmach A,Teich N,Schreiber S,Walldorf J,Schmelz R,Büning C,Fellermann K,Büning J,Helwig U,German IBD Study Group.

    更新日期:2018-03-01 00:00:00

  • The role of hepatitis E virus testing in drug-induced liver injury.

    abstract:BACKGROUND:Locally acquired hepatitis E is an emerging infection in developed countries and can be misdiagnosed as drug-induced liver injury. AIM:To study the role of hepatitis E virus (HEV) testing in drug-induced liver injury. METHODS:Retrospective review of a cohort of patients with suspected drug-induced liver in...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2007.03504.x

    authors: Dalton HR,Fellows HJ,Stableforth W,Joseph M,Thurairajah PH,Warshow U,Hazeldine S,Remnarace R,Ijaz S,Hussaini SH,Bendall RP

    更新日期:2007-11-15 00:00:00

  • Review article: nitroimidazole resistance in Helicobacter pylori.

    abstract::The efficacy of a nitroimidazole-containing regimen for the treatment of Helicobacter pylori infection is decreased by nitroimidazole resistance. Nitroimidazoles are meta- bolized by H. pylori by several nitro-reductases of which an oxygen-insensitive NADPH nitroreductase encoded by the rdxA gene is the most important...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1046/j.1365-2036.2000.00675.x

    authors: Van Der Wouden EJ,Thijs JC,Van Zwet AA,Kleibeuker JH

    更新日期:2000-01-01 00:00:00

  • Raised faecal calprotectin is associated with subsequent symptomatic relapse, in children and adolescents with inflammatory bowel disease in clinical remission.

    abstract:BACKGROUND:Reliable data on inflammatory biomarkers for predicting relapse of paediatric inflammatory bowel disease (IBD) are lacking. AIM:To investigate the predictive value of faecal calprotectin (FC) and CRP for symptomatic relapse in pediatric IBD in clinical remission. METHODS:In this cross-sectional cohort stud...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章

    doi:10.1111/apt.13950

    authors: Diederen K,Hoekman DR,Leek A,Wolters VM,Hummel TZ,de Meij TG,Koot BG,Tabbers MM,Benninga MA,Kindermann A

    更新日期:2017-04-01 00:00:00

  • Systematic review: combination therapies for treatment-naïve chronic hepatitis B.

    abstract:BACKGROUND:There is a renewed interest in use of combination therapies in treatment-naïve chronic hepatitis B (CHB) because of limitations of monotherapies. AIM:To discuss the current status of combination therapies in treatment-naïve CHB. METHODS:PubMed search was done using 'combination', 'sequential' and 'chronic ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1111/j.1365-2036.2008.03695.x

    authors: Kumar M,Sarin SK

    更新日期:2008-06-01 00:00:00

  • Effects of interferon-beta on plasma lipid and lipoprotein composition and post-heparin lipase activities in patients with chronic hepatitis C.

    abstract:BACKGROUND:Interferon therapy has been shown to induce lipid abnormalities. AIM:We assessed the effects of interferon-beta on the lipoprotein profile and post-heparin lipase activities in 26 normolipaemic patients with chronic hepatitis C. METHODS:Interferon-beta was administered subcutaneously at doses of 6 x 106 U ...

    journal_title:Alimentary pharmacology & therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1046/j.1365-2036.2000.00792.x

    authors: Andrade RJ,García-Escaño MD,Valdivielso P,Alcántara R,Sánchez-Chaparro MA,González-Santos P

    更新日期:2000-07-01 00:00:00